ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
On January 6, 2019, Adamas Pharmaceuticals,Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year ended December 31, 2018. The Company’s financial statements for the fourth quarter and full year ended December 31, 2018, have not yet been completed and could result in changes to these preliminary financial results. A copy of the press release is furnished as Exhibit99.1 to this report.
The information in this Item 2.02 and in the press release furnished as Exhibit99.1 to this current report shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Sectionor Sections 11 and 12(a)(2)of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 2.02Financial Statements and Exhibits.
99.1 Press Release dated January 6, 2019.
Adamas Pharmaceuticals Inc Exhibit
EX-99.1 2 adms991erq42018revenue.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019 — GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year —- Preliminary total prescriptions of approximately 5,…
To view the full exhibit click
About ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).